300858 科拓生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入267,38922.25%302,793299,242369,165364,618
减:营业总成本187,40422.71%211,440209,601256,815268,374
    其中:营业成本128,24627.87%126,411135,910177,290181,167
               财务费用(14,879)-24.86%(24,475)(23,455)(3,187)(6,264)
               资产减值损失------------
公允价值变动收益1,437-3.36%2,0131,2621681,548
投资收益1,419-23.47%3,5786,1229,17311,612
    其中:对联营企业和合营企业的投资收益(84)-121.54%317(718)(416)(842)
营业利润88,51010.94%109,463102,602127,577124,704
利润总额88,49611.06%108,828102,041125,656124,174
减:所得税费用12,26444.41%14,4728,56115,76414,634
净利润76,2327.08%94,35693,480109,891109,539
减:非控股权益------------
股东净利润76,2327.08%94,35693,480109,891109,539

市场价值指针
每股收益 (元) *0.2907.41%0.3600.3500.4900.740
每股派息 (元) *----0.1500.1500.3000.500
每股净资产 (元) *6.9313.49%6.7926.57711.3926.513
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容